Dianthus Therapeutics, Inc. Common Stock (DNTH) News

Latest headlines that mention DNTH, newest first · each headline opens the original publisher

DNTH quote

Last price: $72.09
Day change: -3.27%
Next earnings: 2026-11-04

Quote & chart Expected move Insider trading IV rank history

DNTH headlines

latest coverage

Seeking Alpha News 1mo ago

Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

General T2DNTH

Yahoo Finance 1mo ago

Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

General T2DNTH

Seeking Alpha News 1mo ago

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

General T2DNTH

Investing.com 1mo ago

Dianthus Therapeutics director Simon Read sells $326,553 in stock

General T3DNTH

Investing.com 2mo ago

Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares

General T3DNTH

Investing.com 2mo ago

Dianthus Therapeutics earnings beat by $0.77, revenue topped estimates

Earnings T3DNTH

Seeking Alpha 2mo ago

Dianthus Therapeutics GAAP EPS of -$0.90 misses by $0.05, revenue of $0.76M beats by $0.51M

Earnings T2DNTH

Seeking Alpha News 4mo ago

Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions

General T2DNTH SNY

Investing.com 4mo ago

Dianthus Therapeutics stock falls on Sanofi CIDP trial halt

General T3DNTH SNY

Seeking Alpha News 4mo ago

Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

General T2DNTH

Yahoo Finance 4mo ago

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline

General T2DNTH

Investing.com 4mo ago

Dianthus Therapeutics EVP Randhawa sells $2.4m in company stock

General T3DNTH

Seeking Alpha News 4mo ago

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

General T2DNTH

Motley Fool 5mo ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.

General T3DNTH

DNTH news alerts

Get an alert by email or push when a new headline mentions DNTH.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.